Publications by authors named "Mikole Kalesinskas"
Intravenous immunoglobulin (IVIg), a preparation of polyclonal serum IgG pooled from numerous blood donors, has been used for nearly three decades and is proving to be an efficient treatment for many autoimmune blistering diseases, including pemphigus vulgaris (PV). Despite its widespread use and therapeutic success, its mechanisms of action are not completely understood. Some of its anti-inflammatory and immunomodulatory actions have been studied.
View Article and Find Full Text PDFBackground: Pemphigus foliaceus (PF) differs from pemphigus vulgaris (PV) in that it affects only the skin and mucous membranes are not involved. Pemphigus is commonly treated with systemic corticosteroids and immunosuppressive agents (ISAs). More recently, biologics have been used.
View Article and Find Full Text PDFPemphigus foliaceus (PF) is an autoimmune blistering disease limited to the superficial skin without mucosal involvement. It is clinically, histologically, and immunopathologically distinct from pemphigus vulgaris (PV). As data on pediatric PF is often merged with data on both pediatric and adult PV patients, isolating clinical outcomes in pediatric PF is not always possible.
View Article and Find Full Text PDFArticle Synopsis
- Laminin-332 is a crucial part of the basement membrane and has been linked to various autoimmune diseases, with autoantibodies found in conditions like lupus and psoriasis, which also show high cancer rates.
- The study focuses on the connection between Laminin-332 autoantibodies and malignancy, using Laminin-332 Pemphigoid (LM-332Pg) to compare cancer prevalence and clinical outcomes in affected patients.
- Findings indicate that many autoimmune diseases with Laminin-332 autoantibodies have increased cancer risks, particularly for ovarian, uterine, lung, gastric cancers, and leukemia, while breast cancer incidence remains low.